European Patent Office president Benoît Battistelli has praised the “steady” progress that the Unitary Patent and its associated court have made this year.
The US Food and Drug Administration (FDA) has approved the first generic versions of antidepressant drug Cymbalta (duloxetine hydrochloride), after Eli Lilly’s primary patent covering the product expired on December 11.
Canadian law firm Davis LLP has strengthened its life sciences department with the addition of Sara Zborovski as partner.
The High Court in Australia has said for the first time that a method of medical treatment for the human body can be a patentable invention.
Six US congressman have implored President Barack Obama to ensure that the Trans Pacific Partnership does not include measures that undermine access to affordable healthcare.
Europe’s main life sciences laboratory has made a database containing details of around 15 million patented chemical structures available to the public for the first time.
The rapidly-evolving field of life sciences presents a variety of unique IP challenges, which were debated at this year's PanEuropean IP Summit in Paris.
At the PanEuropean IP Summit on Tuesday, a panel discussion revealed different attitudes toward the introduction of the Unitary Patent and Unified Patent Court.
Speaking at Wednesday's C5 Congress on Biotech and Pharma Patenting in London, Michael McGraw, a partner from Fitzpatrick, Cella, Harper and Scinto in New York, considered the line that separates natural and man-made products.
At the 3rd C5 Forum on Biosimilars in London on Wednesday, a panel of lawyers and regulatory experts discussed the lie of the land for biosimilars.